NCT06109337

Brief Summary

The goal of this observational study is to learn about The immune cell landscape of peripheral blood mononuclear cells in children with ADHD compared to typically developing controls. The main question it aims to answer are: 1.Testing the differences in immune cell subpopulations, protein expression and signaling pathways and cell subsets between two groups 2. Exploring the correlations between immune function in PBMC and resting-state brain functional networks in children with ADHD. Participants will be taken peripheral blood about 5 ml , cognitive assessment including Intelligence testing, Stroop color-word test and Trail making test, clinical interview and brain structural and functional MRI.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
19mo left

Started Dec 2023

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress61%
Dec 2023Dec 2027

First Submitted

Initial submission to the registry

October 22, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

October 31, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

December 4, 2023

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2027

Expected
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

April 1, 2025

Status Verified

January 1, 2025

Enrollment Period

3.4 years

First QC Date

October 22, 2023

Last Update Submit

March 27, 2025

Conditions

Outcome Measures

Primary Outcomes (3)

  • the differences in immune cell subpopulations, protein expression , signaling pathways between ADHD and typically developing children

    Blood samples of ADHD patients and normal control groups were collected, peripheral blood mononuclear cells were extracted, and 41 protein markers on cell surface were detected and analyzed by CyTOF technology, and detailed atlas of ADHD immune cells were drawn for immunological index analysis. These indicators include cytokine levels, immune cell subsets, and immune-related gene expression.

    2023.11.1-2023.12.31 Participant recruitment and deta collections

  • Clinical assessment and cognitive function testing

    The Clinical Diagnostic Interview Scale (CDIS) was used to evaluate ADHD types, comorbidities, types, comorbidities and clinical symptoms by child psychiatrists with the title of attending psychiatrist or above. ADHD-RS symptom assessment questionnaire was used to assess the severity of symptoms. Cognitive function tests include child IQ, Stroop color word naming test, and Trail making test (TMT).

    2023.11.1-2023.12.31 Participant recruitment and deta collections

  • Brain MRI structure and resting state data

    High-resolution brain structure images were acquired using 3D Magnetization Prepared Rapid Acquisition Gradient-echo (MPRAGE). The FMRI images were acquired by spin-echo-echo planar imaging (SE-EPI)

    2023.11.1-2023.12.31 Participant recruitment and deta collections

Secondary Outcomes (1)

  • General and demographic data collection

    2023.11.1-2023.12.31 data collection

Study Arms (2)

ADHD children

Take peripheral blood 5ml; IQ and cognitive function test; Head MRI scan

Diagnostic Test: drow blood

typically developing controls

Take peripheral blood 5ml; IQ and cognitive function test; Head MRI scan

Diagnostic Test: drow blood

Interventions

drow bloodDIAGNOSTIC_TEST

Participants will be taken peripheral blood about 5 ml

ADHD childrentypically developing controls

Eligibility Criteria

Age6 Years - 12 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

Children and teenagers ages 6-12 years

You may qualify if:

  • Clinical diagnosis of ADHD; Children with an IQ≥70; Both parents are Han; Agree to take venous blood with informed consent;

You may not qualify if:

  • Schizophrenia, mood disorder, autism, mental retardation; Obvious physical and nervous system abnormalities;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fu Guanghui

Hangzhou, Zhejiang, 310000, China

RECRUITING

Related Publications (2)

  • Ni Chasaide C, Lynch MA. The role of the immune system in driving neuroinflammation. Brain Neurosci Adv. 2020 Jan 29;4:2398212819901082. doi: 10.1177/2398212819901082. eCollection 2020 Jan-Dec.

  • Darwish AH, Elgohary TM, Nosair NA. Serum Interleukin-6 Level in Children With Attention-Deficit Hyperactivity Disorder (ADHD). J Child Neurol. 2019 Feb;34(2):61-67. doi: 10.1177/0883073818809831. Epub 2018 Nov 15.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Peripheral blood monocyte

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental Disorders

Study Officials

  • Hu Guanghui, doctor

    Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Hu Shaohua, doctor

CONTACT

Fu Guanghui, doctor

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 22, 2023

First Posted

October 31, 2023

Study Start

December 4, 2023

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

December 1, 2027

Last Updated

April 1, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will not share

Locations